EVMN
INSIDER BUYEvommune, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeEvommune experienced a significant pipeline setback in September 2026 when EVO756 failed its Phase 2b primary endpoint in both chronic spontaneous urticaria and atopic dermatitis, triggering 17-18% stock declines. The company has pivoted to EVO301, its IL-18BP fusion protein candidate, which demonstrated a clear therapeutic signal and favorable safety profile in Phase 2a data presented in October 2026. Despite the trial failure, the company maintains a strong cash position of $288 million with runway through 2028, though quarterly net losses have widened year-over-year.
Red flags
- •EVO756 Phase 2b primary endpoint failure in both CSU and AD indications, eliminating a major pipeline asset
- •17-18% stock price decline following trial failure announcement
- •Quarterly net loss increased 136% YoY ($32.2M in Q2 2026 vs $13.6M in Q2 2025)
- •Forced pipeline pivot away from EVO756 to EVO301, reducing near-term development diversity
- •Six-month net loss deteriorated 92% YoY ($53.9M H1 2026 vs $28.1M H1 2025)
Insider Activity
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).